Last Update: Jul 08, 2024
Specified Drug-use Survey of Leqvio for s.c. Injection (Familial Hypercholesterolaemia or Hypercholesterolaemia, CKJX839A11401)
ClinicalTrials.gov Identifier:
NCT06275724
Novartis Reference Number:CKJX839A11401
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The objective of this study is to evaluate the long-term safety of Leqvio in patients
with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical
practice Uncontrolled, central registration system, multicenter, special drug use-results
surveillance.

This is a prospective, open-label, multicenter, single-arm observational study
(non-interventional study: NIS) conducted only in Japan.

The survey will include patients with familial hypercholesterolaemia or
hypercholesterolaemia who have received treatment with Leqvio. Patients who discontinued
treatment with Leqvio before completing the 24-month observation period will be followed
for safety until the date of the last dose of Leqvio plus 180 days or until 24 months
after the first dose of Leqvio, whichever comes earlier.

Familial Hypercholesterolaemia, Hypercholesterolaemia
Recruiting
560
Mar 04, 2024
Dec 31, 2027
All
15 Years - (Child, Adult, Older Adult)

Interventions

Other

inclisiran

Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.

Eligibility Criteria

Inclusion Criteria:

- Patients who provided written informed consent to participate in this survey prior
to the start of treatment with Leqvio.

- Patients who received treatment with Leqvio as per the package insert.

Exclusion Criteria:

- Patients who received treatment with a formulation containing the same ingredients
as Leqvio in the past.

- Patients participating in other interventional studies at the time of informed
consent.

- Patients planning to participate in other interventional studies during this survey.

Study Location

Novartis Investigative Site

Recruiting

Toyoake city,Aichi,470 1192,Japan

Novartis Investigative Site

Recruiting

Ichinomiya,Aichi,491-8551,Japan

Novartis Investigative Site

Recruiting

Kure-city,Hiroshima,737-0023,Japan

Novartis Investigative Site

Recruiting

Ono,Hyogo,675-1327,Japan

Novartis Investigative Site

Recruiting

Asahi,Chiba,289-2511,Japan

Novartis Investigative Site

Recruiting

Yokohama,Kanagawa,235-0016,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Fukuoka,800-0031,Japan

Novartis Investigative Site

Recruiting

Nagaoka,Niigata,940-8621,Japan

Novartis Investigative Site

Recruiting

Tsukuba,Ibaraki,305-8576,Japan

Novartis Investigative Site

Recruiting

Ichinomiya,Aichi,494-0001,Japan

Novartis Investigative Site

Recruiting

Kyotanabe,Kyoto,610-0334,Japan

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,004-0052,Japan

Novartis Investigative Site

Recruiting

Fujisawa,Kanagawa,252-0802,Japan

Novartis Investigative Site

Recruiting

Yokosuka,Kanagawa,238-8567,Japan

Novartis Investigative Site

Recruiting

Kobe,Hyogo,654-0026,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,454-0933,Japan

Novartis Investigative Site

Recruiting

Tsushima,Aichi,496-0038,Japan

Novartis Investigative Site

Recruiting

Ikoma,Nara,636-0802,Japan

Novartis Investigative Site

Recruiting

Kyoto-city,Kyoto,602-8566,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,814 0180,Japan

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,062-0003,Japan

Novartis Investigative Site

Recruiting

Yokosuka,Kanagawa,240-0101,Japan

Novartis Investigative Site

Recruiting

Koga,Ibaraki,306-0232,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,461-0045,Japan

Novartis Investigative Site

Recruiting

Kamisu,Ibaraki,314-0146,Japan

Novartis Investigative Site

Recruiting

Urasoe,Okinawa,901-2102,Japan

Novartis Investigative Site

Recruiting

Matsuyama,Ehime,791-8016,Japan

Novartis Investigative Site

Recruiting

Fukushima city,Fukushima,960 1295,Japan

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,065-0027,Japan

Novartis Investigative Site

Recruiting

Komaki,Aichi,485-8520,Japan

Novartis Investigative Site

Recruiting

Oita-city,Oita,870-0263,Japan

Novartis Investigative Site

Recruiting

Kanazawa,Ishikawa,920 8641,Japan

Novartis Investigative Site

Recruiting

Urayasu,Chiba,279-0021,Japan

Novartis Investigative Site

Recruiting

Mito,Ibaraki,310-0015,Japan

Novartis Investigative Site

Recruiting

Handa,Aichi,475-0817,Japan

Novartis Investigative Site

Recruiting

Shirakawa,Fukushima,961-0005,Japan

Novartis Investigative Site

Recruiting

Koriyama,Fukushima,963-8501,Japan

Novartis Investigative Site

Recruiting

Okayama-city,Okayama,700-8558,Japan

Novartis Investigative Site

Recruiting

Amagasaki,Hyogo,660-8511,Japan

Novartis Investigative Site

Recruiting

Kashihara,Nara,634-0045,Japan

Novartis Investigative Site

Recruiting

Uruma,Okinawa,904-2293,Japan

Novartis Investigative Site

Recruiting

Miyakonojo,Miyazaki,885-0002,Japan

Novartis Investigative Site

Recruiting

Takarazuka-city,Hyogo,665-0873,Japan

Novartis Investigative Site

Recruiting

Himeji,Hyogo,670-8560,Japan

Novartis Investigative Site

Recruiting

Kurashiki,Okayama,713-8121,Japan

Novartis Investigative Site

Recruiting

Omura,Nagasaki,856-8562,Japan

Novartis Investigative Site

Recruiting

Asahikawa,Hokkaido,078-8214,Japan

Novartis Investigative Site

Recruiting

Yatsushiro-city,Kumamoto,866-8533,Japan

Novartis Investigative Site

Recruiting

Kitakyushu-city,Fukuoka,807-8556,Japan

Novartis Investigative Site

Recruiting

Moriya-city,Ibaraki,302-0102,Japan

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+81337978748